Retreatment of Patients With Metastatic Cutaneous Melanoma Who Relapse After Elective Checkpoint Inhibitor Discontinuation After a Complete Remission

INTRODUCTION: Checkpoint blockade has improved the response rate and survival in metastatic melanoma. Elective treatment discontinuation appears to be reasonable in most patients who have achieved a confirmed complete remission. It seems crucial to understand whether restarting immune checkpoint inh...

Descripción completa

Detalles Bibliográficos
Autores principales: Sadrolashrafi, Kaviyon, Samlowski, Wolfram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Melanoma and Cutaneous Malignancies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166161/
https://www.ncbi.nlm.nih.gov/pubmed/36852837
http://dx.doi.org/10.1093/oncolo/oyad016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166161/
https://www.ncbi.nlm.nih.gov/pubmed/36852837
http://dx.doi.org/10.1093/oncolo/oyad016

Ejemplares similares